General
Preferred name
AZD-7451
Synonyms
utatrectinib ()
P&D ID
PD121621
CAS
1079274-94-4
Tags
available
drug candidate
Drug Status
investigational
Max Phase
1.0
Drug indication
Glioblastoma multiforme
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Utatrectinib (AZD-7451) is a potent, selective and orally active Trk inhibitor. Utatrectinib blocks TrkC activation and associated tumorigenic behaviors[1].
DESCRIPTION AZD7451 is a pan tropomyosin receptor kinase (TRK; also know as neurotrophic receptor tyrosine kinases or NTRKs) inhibitor . It reached Phase 1 clinical development for anticancer potential, but the programme was discontinued. It was designed for the treatment of tumours that express oncogenic NTRK fusions . The chemical structure of AZD7451 is identical to that which was submitted to the WHO for the INN utatrectinib (proposed INN list 126, Jan 2022). (GtoPdb)
Compound Sets
5
ChEMBL Drugs
CHEMBL3659497
Guide to Pharmacology
10360
MedChem Express Bioactive Compound Library
HY-102066
PKIDB
ReFrame library
External IDs
14
Properties
(calculated by RDKit )
Molecular Weight
382.17
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
2
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
4
cLogP
3.03
TPSA
106.43
Fraction CSP3
0.28
Chiral centers
1.0
Largest ring
6.0
QED
0.53
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Neuronal Signaling
Protein Tyrosine Kinase/RTK
Target
Trk Receptor
Source data